Search Results - "Cella, David"

The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation by Webster, Kimberly, Cella, David, Yost, Kathleen

“…The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System is a collection of health-related quality of life (HRQOL) questionnaires…”
Get full text

Measuring financial toxicity as a clinically relevant patient‐reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST) by Souza, Jonas A., Yap, Bonnie J., Wroblewski, Kristen, Blinder, Victoria, Araújo, Fabiana S., Hlubocky, Fay J., Nicholas, Lauren H., O'Connor, Jeremy M., Brockstein, Bruce, Ratain, Mark J., Daugherty, Christopher K., Cella, David

“…BACKGROUND Cancer and its treatment lead to increased financial distress for patients. To the authors' knowledge, to date, no standardized patient‐reported…”
Get full text

The development of a financial toxicity patient‐reported outcome in cancer: The COST measure by Souza, Jonas A., Yap, Bonnie J., Hlubocky, Fay J., Wroblewski, Kristen, Ratain, Mark J., Cella, David, Daugherty, Christopher K.

“…BACKGROUND Considering patients' experience is essential for optimal decision‐making. However, despite increasing recognition of the impact of costs on…”
Get full text

Development of Physical and Mental Health Summary Scores from the Patient-Reported Outcomes Measurement Information System (PROMIS) Global Items by Hays, Ron D., Bjorner, Jakob B., Revicki, Dennis A., Spritzer, Karen L., Cella, David

“…Background The use of global health items permits an efficient way of gathering general perceptions of health. These items provide useful summary information…”
Get full text

Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209) by Miller, David S, Filiaci, Virginia L, Mannel, Robert S, Cohn, David E, Matsumoto, Takashi, Tewari, Krishnansu S, DiSilvestro, Paul, Pearl, Michael L, Argenta, Peter A, Powell, Matthew A, Zweizig, Susan L, Warshal, David P, Hanjani, Parviz, Carney, Michael E, Huang, Helen, Cella, David, Zaino, Richard, Fleming, Gini F

“…Limitations of the paclitaxel-doxorubicin-cisplatin (TAP) regimen in the treatment of endometrial cancer include tolerability and cumbersome scheduling. The…”
Get full text

Prevalence and characteristics of moderate to severe fatigue: A multicenter study in cancer patients and survivors by Wang, Xin Shelley, Zhao, Fengmin, Fisch, Michael J., O'Mara, Ann M., Cella, David, Mendoza, Tito R., Cleeland, Charles S.

“…BACKGROUND The effective management of fatigue in patients with cancer requires a clear delineation of what constitutes nontrivial fatigue. The authors defined…”
Get full text

Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial by Cuzick, Jack, Prof, Sestak, Ivana, PhD, Cella, David, PhD, Fallowfield, Lesley, Prof

“…Summary Background When the mechanism of action behind treatment toxicity reflects the intended effect on the treatment target, the toxicity might be a useful…”
Get full text

Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer by Pickard, A Simon, Neary, Maureen P, Cella, David

“…Understanding what constitutes an important difference on a HRQL measure is critical to its interpretation. The aim of this study was to provide a range of…”
Get full text

Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial by Cella, David, Prof, Grünwald, Viktor, Prof, Nathan, Paul, MD, Doan, Justin, MPH, Dastani, Homa, PhD, Taylor, Fiona, MBiochem, Bennett, Bryan, PhD, DeRosa, Michael, PhD, Berry, Scott, PhD, Broglio, Kristine, PhD, Berghorn, Elmer, BSN, Motzer, Robert J, Prof

“…Summary Background In the phase 3 CheckMate 025 study, previously treated patients with advanced renal cell carcinoma who were randomly assigned to nivolumab…”
Get full text

Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108) by Khan, Seema A, Zhao, Fengmin, Goldstein, Lori J, Cella, David, Basik, Mark, Golshan, Mehra, Julian, Thomas B, Pockaj, Barbara A, Lee, Christine A, Razaq, Wajeeha, Sparano, Joseph A, Babiera, Gildy V, Dy, Irene A, Jain, Sarika, Silverman, Paula, Fisher, Carla S, Tevaarwerk, Amye J, Wagner, Lynne I, Sledge, George W

“…Distant metastases are present in 6% or more of patients with newly diagnosed breast cancer. In this context, locoregional therapy for the intact primary tumor…”
Get full text

Item Banks for Measuring Emotional Distress From the Patient-Reported Outcomes Measurement Information System (PROMIS®): Depression, Anxiety, and Anger by Pilkonis, Paul A., Choi, Seung W., Reise, Steven P., Stover, Angela M., Riley, William T., Cella, David

“…The authors report on the development and calibration of item banks for depression, anxiety, and anger as part of the Patient-Reported Outcomes Measurement…”
Get full text

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial by Haas, Naomi B, Dr, Manola, Judith, MS, Uzzo, Robert G, Prof, Flaherty, Keith T, MD, Wood, Christopher G, Prof, Kane, Christopher, Prof, Jewett, Michael, Prof, Dutcher, Janice P, Prof, Atkins, Michael B, Prof, Pins, Michael, Prof, Wilding, George, Prof, Cella, David, Prof, Wagner, Lynne, Prof, Matin, Surena, Prof, Kuzel, Timothy M, Prof, Sexton, Wade J, Prof, Wong, Yu-Ning, MD, Choueiri, Toni K, MD, Pili, Roberto, Prof, Puzanov, Igor, MD, Kohli, Manish, MD, Stadler, Walter, Prof, Carducci, Michael, Prof, Coomes, Robert, DiPaola, Robert S, Prof

“…Summary Background Renal-cell carcinoma is highly vascular, and proliferates primarily through dysregulation of the vascular endothelial growth factor (VEGF)…”
Get full text

Bringing PROMIS to practice: Brief and precise symptom screening in ambulatory cancer care by Wagner, Lynne I., Schink, Julian, Bass, Michael, Patel, Shalini, Diaz, Maria Varela, Rothrock, Nan, Pearman, Timothy, Gershon, Richard, Penedo, Frank J., Rosen, Steven, Cella, David

“…BACKGROUND Supportive oncology practice can be enhanced by the integration of a brief and validated electronic patient‐reported outcome assessment into the…”
Get full text

The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008 by Cella, David, Riley, William, Stone, Arthur, Rothrock, Nan, Reeve, Bryce, Yount, Susan, Amtmann, Dagmar, Bode, Rita, Buysse, Daniel, Choi, Seung, Cook, Karon, DeVellis, Robert, DeWalt, Darren, Fries, James F, Gershon, Richard, Hahn, Elizabeth A, Lai, Jin-Shei, Pilkonis, Paul, Revicki, Dennis, Rose, Matthias, Weinfurt, Kevin, Hays, Ron

“…Abstract Objectives Patient-reported outcomes (PROs) are essential when evaluating many new treatments in health care; yet, current measures have been limited…”
Get full text

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial by Rini, Brian I, Dr, Escudier, Bernard, MD, Tomczak, Piotr, MD, Kaprin, Andrey, Prof, Szczylik, Cezary, MD, Hutson, Thomas E, DO, Michaelson, M Dror, MD, Gorbunova, Vera A, Prof, Gore, Martin E, Prof, Rusakov, Igor G, Prof, Negrier, Sylvie, Prof, Ou, Yen-Chuan, Prof, Castellano, Daniel, MD, Lim, Ho Yeong, Prof, Uemura, Hirotsugu, Prof, Tarazi, Jamal, MD, Cella, David, PhD, Chen, Connie, PharmD, Rosbrook, Brad, MS, Kim, Sinil, MD, Motzer, Robert J, MD

“…Summary Background The treatment of advanced renal cell carcinoma has been revolutionised by targeted therapy with drugs that block angiogenesis. So far, no…”
Get full text

Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial by LOEHRER, Patrick J, YANG FENG, BENSON, Al B, CARDENES, Higinia, WAGNER, Lynne, BRELL, Joanna M, CELLA, David, FLYNN, Patrick, RAMANATHAN, Ramesh K, CRANE, Christopher H, ALBERTS, Steven R

“…The purpose of this trial was to evaluate the role of radiation therapy with concurrent gemcitabine (GEM) compared with GEM alone in patients with localized…”
Get full text

Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial by MOTZER, Robert J, NOSOV, Dmitry, KOGAN, Mikhail, ALEKSEEV, Boris Y, STERNBERG, Cora N, SZCZYLIK, Cezary, CELLA, David, IVANESCU, Cristina, KRIVOSHIK, Andrew, STRAHS, Andrew, ESTEVES, Brooke, BERKENBLIT, Anna, EISEN, Timothy, HUTSON, Thomas E, BONDARENKO, Igor, LESOVOY, Vladimir, LIPATOV, Oleg, TOMCZAK, Piotr, LYULKO, Oleksiy, ALYASOVA, Anna, HARZA, Mihai

“…Tivozanib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR1), -2, and -3. This phase III trial…”
Get full text

Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study by MONK, Bradley J, SILL, Michael W, MCMEEKIN, D. Scott, COHN, David E, RAMONDETTA, Lois M, BOARDMAN, Cecelia H, BENDA, Jo, CELLA, David

“…Assess toxicity and efficacy of cisplatin (Cis) doublet combinations in advanced and recurrent cervical carcinoma. Patients were randomly assigned to…”
Get full text

ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research by Reeve, Bryce B., Wyrwich, Kathleen W., Wu, Albert W., Velikova, Galina, Terwee, Caroline B., Snyder, Claire F., Schwartz, Carolyn, Revicki, Dennis A., Moinpour, Carol M., McLeod, Lori D., Lyons, Jessica C., Lenderking, William R., Hinds, Pamela S., Hays, Ron D., Greenhalgh, Joanne, Gershon, Richard, Feeny, David, Fayers, Peter M., Cella, David, Brundage, Michael, Ahmed, Sara, Aaronson, Neil K., Butt, Zeeshan

“…Purpose An essential aspect of patient-centered outcomes research (PCOR) and comparative effectiveness research (CER) is the integration of patient…”
Get full text

Progress in Assessing Physical Function in Arthritis: PROMIS Short Forms and Computerized Adaptive Testing by FRIES, James F, CELLA, David, ROSE, Matthias, KRISHNAN, Eswar, BRUCE, Bonnie

“…Objective. Assessing self-reported physical function/disability with the Health Assessment Questionnaire Disability Index (HAQ) and other instruments has…”
Get full text